The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Vertex Pharmaceuticals announced a multiyear partnership with Affinia Therapeutics to develop gene therapies for cystic fibrosis (CF) and other…
Orkambi (ivacaftor/lumacaftor) can improve glucose tolerance in people with cystic fibrosis, a small study in patients either at…
Supplemental estrogen, most commonly taken for contraception, is associated with poorer bone mineral density in people with cystic fibrosis…
A measure called the lung clearance index (LCI) can predict low blood oxygen levels during sleep in people with…
Delivering nutrients through dialysis could help people with co-occurring cystic fibrosis (CF) and kidney disease meet their nutritional requirements,…
An unusual clinical presentation can hinder proper diagnosis for people with cystic fibrosis (CF), even with newborn screening, a…
Liver ultrasounds can help identify children with cystic fibrosis (CF) who are at higher risk of developing liver disease,…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to MRT5005, an investigational RNA-based…
Enrollment is complete for a European initiative to test an organoid-based, personalized-medicine approach to treating cystic fibrosis, with the…